Loading candles…
Sanofi Consumer Healthcare India Ltd is an Indian pharmaceutical and consumer healthcare company incorporated in 2023 following its demerger from Sanofi India Limited. As a division of the global pharmaceutical company Sanofi, it operates as a standalone entity focusing on manufacturing and trading drugs and pharmaceutical products, primarily over-the-counter and consumer healthcare items. The company's portfolio spans business segments including self-care, allergy, digestive wellness, pain care, and multivitamins. It manages legacy brands that hold leadership positions in their therapeutic categories and employs a hybrid model combining prescription-driven demand with consumer self-choice.
This page is a live market overview for SANOFI CONS HEALTHC IND L (SANOFICONR) on the NSE. As a listed security, SANOFI CONS HEALTHC IND L is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for SANOFICONR before placing trades on tick2trade.
As of the latest feed, SANOFICONR last traded at ₹4,514.2 on NSE, down ₹19.6 (0.43%) from the previous close of ₹4,533.8. Today's session range is ₹4,510 – ₹4,550, against a 52-week band of ₹3,975 – ₹5,512. Traded volume today stands at 1.33K shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for SANOFICONR in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether SANOFICONR is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for SANOFI CONS HEALTHC IND L before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in SANOFICONR. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated SANOFICONR option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Unaudited Results - Q1 & FY26 | To consider and approve the Unaudited Financial Results for the quarter and half year ended Jun 30, 2026 | 28 Jul 2026 |
| Unaudited Results - Q4-FY26 | To consider and approve the Unaudited Financial Results of the Company for the quarter ended March 31, 2026 | 28 Apr 2026 |
| Audited Results - Q3 & FY25 | To consider and approve the Audited Financial Statements for the Quarter and Financial Year ended December 31, 2025 | 25 Feb 2026 |
| Dividend | To consider recommendation of dividend, if any, for the Financial Year ended 31st December 2025 at Board Meeting to be held on Wednesday, 25th February 2026. | 25 Feb 2026 |
| Unaudited Results - Q2-FY25 | To consider and approve the Unaudited Financial Results for the quarter and nine months ended 30th September 2025 | 12 Nov 2025 |
| Unaudited Results - Q1 & FY25 | To consider and approve the Unaudited Financial Results for the quarter and half-year ended 30th June 2025 | 4 Aug 2025 |
| Unaudited Results - Q4-FY25 | To consider and approve the Unaudited Financial Results for the Quarter ended 31st March 2025 | 2 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.